%0 Conference Paper %F Oral %T Disease-Modifying Therapies, Outcomes, Risk Factors and Severity of COVID-19 in Multiple Sclerosis: A MENACTRIMS Registry Based Study %+ Epidémiologie des Maladies Chroniques en zone tropicale (EpiMaCT) %+ Neuroépidémiologie Tropicale (NET) %+ Lebanese University [Beirut] (LU) %+ Lebanese American University (LAU) %+ Harley Street Medical Center Abu Dhabi %+ American University of Beirut Medical Center %+ Amiri hospital %+ Department of Neurology [Egypte] %+ Multiple Sclerosis Research Center of Tehran University of Medical Sciences %+ Royal Hospital [Muscat, Oman] (RH) %+ Établissement Hospitalo-Universitaire d’Oran (EHU) %A Zeineddine, Maya %A Boumédiène, Farid %A Al‐hajje, Amal %A Salameh, Pascale %A Massouh, Joelle %A Saab, Georges %A Alroughani, Raed %A Al- Mahdawi, Akram %A Shalaby, Nevin %A Inshasi, Jihad %A Sahraian, Mohammad Ali %A Gouider, Riadh %A Mrabet, Saloua %A Al-Khabouri, Jaber %A Shaygannejad, Vahid %A Chentouf, Amina %A Yamout, Bassem %< avec comité de lecture %B Seventh MENACTRIMS Congress %C LE CAIRE, Egypt %8 2022-11-11 %D 2022 %Z Life Sciences [q-bio] %Z Life Sciences [q-bio]/Santé publique et épidémiologieConference papers %X Multiple sclerosis (MS) patients have been considered a higher-risk population for COVID-19 due to the high prevalence of disability and disease-modifying therapy use; however, there is little data in our Middle East and North Africa region (MENA) identifying clinical characteristics of MS associated with worse COVID-19 outcomes. %G English %L hal-04092941 %U https://unilim.hal.science/hal-04092941 %~ UNILIM %~ SANTE_PUB_INSERM %~ GEIST %~ EPIMACT %~ OMEGAHEALTH %~ LABCIS